This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Day One Biopharmaceuticals (DAWN) 주식 개요
상업화 단계의 바이오 제약 회사인 데이 원 바이오파마슈티컬스는 미국에서 소아 및 성인 질환에 대한 의약품의 식별, 개발 및 상용화에 주력하고 있습니다. 자세히 보기
DAWN Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% 저평가 내재 할인율
5419.8%Revenue growth p.a.
6.2k
18
0
126
Day One Biopharmaceuticals, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$21.53 |
| 52주 최고가 | US$21.53 |
| 52주 최저가 | US$5.64 |
| 베타 | -1.75 |
| 1개월 변동 | 0.61% |
| 3개월 변동 | 80.17% |
| 1년 변동 | 178.17% |
| 3년 변동 | 73.63% |
| 5년 변동 | n/a |
| IPO 이후 변동 | -16.84% |
최근 뉴스 및 업데이트
DAWN: Servier Cash Offer Will Define Deal Outcome And Future Pipeline Path
Analysts have reset their Day One Biopharmaceuticals price targets to $21.50, generally aligning with Servier's agreed $21.50 per share cash acquisition price. They are also shifting ratings to more neutral stances, as upside potential is now seen as capped by the deal terms.DAWN: Servier Cash Offer Will Frame Deal Completion And Pipeline Optionality
Analysts have reset their price targets on Day One Biopharmaceuticals to $21.50, a move of up to $3.00 from prior estimates. They are aligning their models with the agreed $21.50 per share cash acquisition by Servier and see limited scope for additional upside from standalone growth assumptions.DAWN: Servier Cash Offer Will Define Future Upside And Downside Potential
The analyst price target for Day One Biopharmaceuticals has shifted from $22.25 to $21.50, with analysts aligning their views to the agreed $21.50 per share cash acquisition price from Servier and adjusting their assumptions around revenue growth, profit margins, discount rate, and future P/E accordingly. Analyst Commentary Following the Servier agreement, Street research has largely converged around the US$21.50 cash offer, with multiple firms cutting ratings to Neutral or Hold and aligning price targets with the acquisition price.Recent updates
DAWN: Servier Cash Offer Will Define Deal Outcome And Future Pipeline Path
Analysts have reset their Day One Biopharmaceuticals price targets to $21.50, generally aligning with Servier's agreed $21.50 per share cash acquisition price. They are also shifting ratings to more neutral stances, as upside potential is now seen as capped by the deal terms.DAWN: Servier Cash Offer Will Frame Deal Completion And Pipeline Optionality
Analysts have reset their price targets on Day One Biopharmaceuticals to $21.50, a move of up to $3.00 from prior estimates. They are aligning their models with the agreed $21.50 per share cash acquisition by Servier and see limited scope for additional upside from standalone growth assumptions.DAWN: Servier Cash Offer Will Define Future Upside And Downside Potential
The analyst price target for Day One Biopharmaceuticals has shifted from $22.25 to $21.50, with analysts aligning their views to the agreed $21.50 per share cash acquisition price from Servier and adjusting their assumptions around revenue growth, profit margins, discount rate, and future P/E accordingly. Analyst Commentary Following the Servier agreement, Street research has largely converged around the US$21.50 cash offer, with multiple firms cutting ratings to Neutral or Hold and aligning price targets with the acquisition price.
DAWN: Ojemda Franchise And Mersana Integration Will Recast Future Earnings Power
Analysts nudged their price target on Day One Biopharmaceuticals up by $1 to $30, reflecting updated assumptions around revenue growth, profitability, and future P/E, now that recent Street research has incorporated both the latest quarterly results and ongoing Ojemda development plans. Analyst Commentary Bullish analysts are framing the latest price target move to $30 as part of a broader, constructive view on Day One Biopharmaceuticals, grounded in updated revenue, profitability, and P/E assumptions around the Ojemda franchise and recent quarterly results.Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
Feb 27
DAWN: Future Cash Flows From Mersana Acquisition Will Drive Upside Potential
Analysts raised their fair value estimate for Day One Biopharmaceuticals by $1 to $17.00, citing updated assumptions that combine higher revenue expectations, a higher future P/E, and a slightly higher discount rate. Analyst Commentary Recent Street research on Day One Biopharmaceuticals reflects a mix of optimism about the company’s potential and caution about execution risks and valuation.DAWN: Mersana Acquisition Will Recast Pipeline Risk Profile And Future Earnings Power
Narrative Update: Day One Biopharmaceuticals Analysts have adjusted their price target on Day One Biopharmaceuticals from US$27 to US$29, reflecting updated views on the Mersana acquisition, revised assumptions for future revenue growth and profit margins, and a higher future P/E multiple, even as some recent research has featured lower individual price targets. Analyst Commentary Recent Street research around Day One Biopharmaceuticals has centered on the acquisition of Mersana Therapeutics and how that deal reshapes the company’s pipeline, risk profile, and potential long term earnings power.Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking
Jan 21
DAWN: Mersana Acquisition And OJEMDA Durability Data Will Reshape Pipeline Risk Profile
Analysts have adjusted their price target on Day One Biopharmaceuticals from US$34.00 to US$27.00, citing updated assumptions on growth, margins and future P/E, along with support for the recently announced, higher cost acquisition of Mersana Therapeutics as a way to diversify the pipeline beyond OJEMDA. Analyst Commentary Bullish analysts are framing the Mersana deal as a sign that Day One is willing to pay up to secure assets that fit tightly with its focus on targeted oncology, even if the acquisition cost of up to US$285 million looks full on headline terms.DAWN: Mersana Deal Will Diversify ADC Platform And Support Future Upside
Analysts nudged their price target on Day One Biopharmaceuticals slightly higher to $22.25 per share, citing cautious optimism that the $285 million Mersana acquisition could diversify the pipeline beyond OJEMDA and enhance long term growth prospects despite its premium valuation. Analyst Commentary Bullish Takeaways Bullish analysts view the acquisition of Mersana as a strategic way to add a second antibody drug conjugate, Emi Le, alongside PTK7.We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
Dec 19DAWN: Mersana Acquisition Will Diversify ADC Pipeline And Support Long Term Upside
Analysts slightly raised their price target for Day One Biopharmaceuticals to $22.25 per share, citing the strategically bold, though expensive, acquisition of Mersana Therapeutics as a catalyst for pipeline diversification beyond OJEMDA and as a potential source of long term value. Analyst Commentary Analyst reactions to the Mersana deal highlight a mix of strategic enthusiasm and execution risk, with many viewing the transaction as a meaningful but high stakes swing for Day One's long term growth profile and valuation.DAWN: Acquisition of ADC Candidate Will Broaden Pipeline and Patient Reach
Analysts have lowered their price target for Day One Biopharmaceuticals from $24.25 to $22.25. They cited uncertainty over the recent $285 million Mersana acquisition, despite noting improved profit margin and revenue projections.Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Fly 29% But Investors Aren't Buying For Growth
Nov 08Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Held Back By Insufficient Growth Even After Shares Climb 30%
Sep 06Expanded Clinical Indications And European Approvals Will Shape Future Oncology
Despite a substantially improved net profit margin and a lower future P/E ratio indicating enhanced profitability and valuation, the consensus analyst price target for Day One Biopharmaceuticals has been reduced from $26.25 to $24.00. Valuation Changes Summary of Valuation Changes for Day One Biopharmaceuticals The Consensus Analyst Price Target has fallen from $26.25 to $24.00.We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 18
FDA Approval And Ipsen Licensing Will Expand Pediatric Treatment Options
FDA approval and the launch of OJEMDA boost long-term revenue growth, addressing unmet medical needs and strong market uptake in pediatric glioma.Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer
Feb 03Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Jan 07Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Nov 04We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19주주 수익률
| DAWN | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | 0.3% | -2.5% | 0.8% |
| 1Y | 178.2% | 26.8% | 27.7% |
수익률 대 산업: DAWN은 지난 1년 동안 26.8%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: DAWN은 지난 1년 동안 27.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| DAWN volatility | |
|---|---|
| DAWN Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
안정적인 주가: DAWN의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: DAWN의 주간 변동성은 지난 1년간 14%에서 21%로 증가했습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2018 | 178 | Jeremy Bender | dayonebio.com |
상업화 단계의 바이오 제약 회사인 데이원 바이오파마슈티컬스는 미국에서 소아 및 성인 질환 치료제의 식별, 개발 및 상용화에 주력하고 있습니다. 이 회사의 주요 제품 후보로는 재발성 또는 불응성 저등급 신경교종 소아 환자를 대상으로 임상 2상 시험 중인 경구용 및 뇌 침투성 II형 신속 촉진 섬유육종 키나제 억제제인 토보라페닙과 임상 3상 시험 단계에 있는 프론트라인 라프 변경 pLGG인 입센이 있습니다. 또한 진행성 고형암 환자 치료를 위해 매우 안정적이고 친수성 변형 발린-알라닌(VA) 절단 가능 링커를 통해 토포이소머라제 I 억제제와 결합된 새로운 인간화 항-PK7 면역글로불린 G1 단클론 항체로 구성된 PTK7 표적 ADC인 DAY301을 개발 중입니다; 그리고 유방암, 난소암, 자궁내막암, 아데노이드 낭성 암종(ACC) 치료를 위해 임상 1상 시험 중인 메르사나 테라퓨틱스가 개발한 독점적 링커-페이로드 플랫폼의 구성 요소로서 오리스타틴 항-투불린 페이로드에 결합된 B7-H4를 표적으로 하는 항체-약물 접합체 Emi-Le입니다.
Day One Biopharmaceuticals, Inc. 기초 지표 요약
| DAWN 기초 통계 | |
|---|---|
| 시가총액 | US$2.22b |
| 순이익 (TTM) | -US$107.32m |
| 매출 (TTM) | US$158.18m |
14.1x
주가매출비율(P/S)-20.7x
주가수익비율(P/E)DAWN는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| DAWN 손익계산서 (TTM) | |
|---|---|
| 매출 | US$158.18m |
| 매출원가 | US$17.21m |
| 총이익 | US$140.97m |
| 기타 비용 | US$248.29m |
| 순이익 | -US$107.32m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -1.04 |
| 총이익률 | 89.12% |
| 순이익률 | -67.85% |
| 부채/자본 비율 | 0% |
DAWN의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/04/25 11:42 |
| 종가 | 2026/04/22 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Day One Biopharmaceuticals, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Alec Stranahan | BofA Global Research |
| Naureen Quibria | Capital One Securities, Inc. |
| Andrea Newkirk | Goldman Sachs |